{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T23:18:19Z","timestamp":1772061499064,"version":"3.50.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,3,5]],"date-time":"2022-03-05T00:00:00Z","timestamp":1646438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,3,5]],"date-time":"2022-03-05T00:00:00Z","timestamp":1646438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32 CA160056"],"award-info":[{"award-number":["T32 CA160056"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s11912-022-01196-1","type":"journal-article","created":{"date-parts":[[2022,3,5]],"date-time":"2022-03-05T09:02:42Z","timestamp":1646470962000},"page":"695-702","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Approaches to First-Line Therapy for Metastatic Clear Cell Renal Cell Carcinoma"],"prefix":"10.1007","volume":"24","author":[{"given":"Yu-Wei","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian I.","family":"Rini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,3,5]]},"reference":[{"issue":"19","key":"1196_CR1","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803\u201313.","journal-title":"N Engl J Med"},{"key":"1196_CR2","unstructured":"Motzer RJ, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378(14):1277\u20131290. CheckMate 214 demonstrated overall survival benefit of ipilimumab\/nivolumab over sunitinib in advanced RCC."},{"key":"1196_CR3","unstructured":"Rini BI, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1116\u20131127. Keynote 426 demonstrated overall survival benefit of pembrolizumab\/axitinib over sunitinib in advanced RCC."},{"key":"1196_CR4","unstructured":"Choueiri TK, et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2021;384(9):829\u2013841. CheckMate 9ER demonstrated overall survival benefit of nivolumab\/cabozantinib over sunitinib in advanced RCC."},{"key":"1196_CR5","unstructured":"Motzer R, et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med. 2021;384(14):1289\u20131300. CLEAR trial demonstrated overall survival benefit of pembrolizumab\/lenvatinib over sunitinib in advanced RCC."},{"issue":"10","key":"1196_CR6","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1016\/S1470-2045(19)30413-9","volume":"20","author":"RJ Motzer","year":"2019","unstructured":"Motzer RJ, et al. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol. 2019;20(10):1370\u201385.","journal-title":"Lancet Oncol"},{"key":"1196_CR7","doi-asserted-by":"crossref","unstructured":"Albiges L, et al. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open. 2020;5(6):e001079. Extended follow-up of CheckMate 214. This updated results showed durable efficacy of ipilimumab\/nivolumab after a minimum of 48 months of follow-up.","DOI":"10.1136\/esmoopen-2020-001079"},{"issue":"34","key":"1196_CR8","doi-asserted-by":"publisher","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","volume":"27","author":"DY Heng","year":"2009","unstructured":"Heng DY, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009;27(34):5794\u20139.","journal-title":"J Clin Oncol"},{"issue":"12","key":"1196_CR9","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","volume":"380","author":"RJ Motzer","year":"2019","unstructured":"Motzer RJ, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1103\u201315.","journal-title":"N Engl J Med"},{"issue":"10189","key":"1196_CR10","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1016\/S0140-6736(19)30723-8","volume":"393","author":"BI Rini","year":"2019","unstructured":"Rini BI, et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet. 2019;393(10189):2404\u201315.","journal-title":"Lancet"},{"key":"1196_CR11","doi-asserted-by":"publisher","first-page":"102242","DOI":"10.1016\/j.ctrv.2021.102242","volume":"99","author":"K Mori","year":"2021","unstructured":"Mori K, et al. Differences in oncological and toxicity outcomes between programmed cell death-1 and programmed cell death ligand-1 inhibitors in metastatic renal cell carcinoma: a systematic review and meta-analysis. Cancer Treat Rev. 2021;99:102242.","journal-title":"Cancer Treat Rev"},{"issue":"9","key":"1196_CR12","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1158\/1078-0432.CCR-19-3323","volume":"26","author":"DH Aggen","year":"2020","unstructured":"Aggen DH, Drake CG, Rini BI. Targeting PD-1 or PD-L1 in metastatic kidney cancer: combination therapy in the first-line setting. Clin Cancer Res. 2020;26(9):2087\u201395.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"1196_CR13","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/S1470-2045(20)30436-8","volume":"21","author":"T Powles","year":"2020","unstructured":"Powles T, et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. Lancet Oncol. 2020;21(12):1563\u201373.","journal-title":"Lancet Oncol"},{"key":"1196_CR14","doi-asserted-by":"crossref","unstructured":"Rini BI, et al. Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): results from 42-month follow-up of KEYNOTE-426. J Clin Oncol. 39:2021 (suppl 15; abstr 4500). Extended follow-up of Keynote 426. Pembrolizumab\/axitinib had the longest follow-up data among current IO\/TKI combinations.","DOI":"10.1200\/JCO.2021.39.15_suppl.4500"},{"issue":"20","key":"1196_CR15","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.2217\/fon-2019-0021","volume":"15","author":"A Desai","year":"2019","unstructured":"Desai A, Small EJ. Treatment of advanced renal cell carcinoma patients with cabozantinib, an oral multityrosine kinase inhibitor of MET AXL and VEGF receptors. Future Oncol. 2019;15(20):2337\u201348.","journal-title":"Future Oncol"},{"key":"1196_CR16","doi-asserted-by":"crossref","unstructured":"Apolo AB, et al. Nivolumab plus cabozantinib (N+C) versus sunitinib (S) for advanced renal cell carcinoma (aRCC): Outcomes by baseline disease characteristics in the phase 3 CheckMate 9ER trial. J Clin Oncol. 2021;39 (15_suppl):4553\u201353.\u00a0Updated follow-up of CheckMate 9ER.","DOI":"10.1200\/JCO.2021.39.15_suppl.4553"},{"key":"1196_CR17","doi-asserted-by":"crossref","unstructured":"Taylor MH, et al. Phase IB\/II trial of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma, endometrial cancer, and other selected advanced solid tumors. J Clin Oncol. 2021;4(5):1154\u201363.","DOI":"10.1200\/JCO.19.01598"},{"key":"1196_CR18","doi-asserted-by":"crossref","unstructured":"Quhal F, et al. First-line immunotherapy-based combinations for metastatic renal cell carcinoma: a systematic review and network meta-analysis. Eur Urol Oncol. 2021; 4(5):755\u201365","DOI":"10.1016\/j.euo.2021.03.001"},{"issue":"6","key":"1196_CR19","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.eururo.2021.03.016","volume":"80","author":"IB Riaz","year":"2021","unstructured":"Riaz IB, et al. A living, interactive systematic review and network meta-analysis of first-line treatment of metastatic renal cell carcinoma. Eur Urol. 2021;80(6):712\u201323.","journal-title":"Eur Urol."},{"issue":"4","key":"1196_CR20","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1097\/MOU.0000000000000889","volume":"31","author":"F Quhal","year":"2021","unstructured":"Quhal F, et al. Adverse events of systemic immune-based combination therapies in the first-line treatment of patients with metastatic renal cell carcinoma: systematic review and network meta-analysis. Curr Opin Urol. 2021;31(4):332\u20139.","journal-title":"Curr Opin Urol"},{"issue":"12","key":"1196_CR21","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1056\/NEJMe1900887","volume":"380","author":"B Escudier","year":"2019","unstructured":"Escudier B. Combination therapy as first-line treatment in metastatic renal-cell carcinoma. N Engl J Med. 2019;380(12):1176\u20138.","journal-title":"N Engl J Med"},{"key":"1196_CR22","doi-asserted-by":"crossref","unstructured":"Gr\u00fcnwald V, et al. Analysis of the CLEAR study in patients (pts) with advanced renal cell carcinoma (RCC): depth of response and efficacy for selected subgroups in the lenvatinib (LEN) + pembrolizumab (PEMBRO) and sunitinib (SUN) treatment arms.J Clin Oncol. 2021; 39(15_suppl):4560\u20134560. Updated results of CLEAR trial.","DOI":"10.1200\/JCO.2021.39.15_suppl.4560"},{"issue":"36","key":"1196_CR23","doi-asserted-by":"publisher","first-page":"3045","DOI":"10.2217\/fon-2020-0725","volume":"16","author":"JP Hall","year":"2020","unstructured":"Hall JP, et al. Treatment patterns, outcomes and clinical characteristics in advanced renal cell carcinoma: a real-world US study. Future Oncol. 2020;16(36):3045\u201360.","journal-title":"Future Oncol"},{"issue":"1","key":"1196_CR24","doi-asserted-by":"publisher","first-page":"100030","DOI":"10.1016\/j.esmoop.2020.100030","volume":"6","author":"S Aeppli","year":"2021","unstructured":"Aeppli S, et al. First-line treatment of metastatic clear cell renal cell carcinoma: a decision-making analysis among experts. ESMO Open. 2021;6(1):100030.","journal-title":"ESMO Open"},{"key":"1196_CR25","doi-asserted-by":"crossref","unstructured":"Motzer RJ, et al. Molecular subsets in renal cancer determine outcome to checkpoint and angiogenesis blockade. Cancer Cell. 2020;38(6):803\u2013817.e4. Correlative study of IMmmtion 151 which used tumor RNA-seq to seggregate mRCC tumors into seven molecular distinct clusters based on gene expression signatures\/enriched pathways and demonstrated differential efficacy with the addition of atezolizumab.","DOI":"10.1016\/j.ccell.2020.10.011"},{"key":"1196_CR26","unstructured":"Network, N.C.C. NCCN clinical practice guidelines in oncology (NCCN Guidelines) kidney cancer. 2021 [cited 2021 07\/19]; Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/kidney.pdf."},{"issue":"3","key":"1196_CR27","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.annonc.2020.11.016","volume":"32","author":"T Powles","year":"2021","unstructured":"Powles T. Recent eUpdate to the ESMO clinical practice guidelines on renal cell carcinoma on cabozantinib and nivolumab for first-line clear cell renal cancer: renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(3):422\u20133.","journal-title":"Ann Oncol"},{"key":"1196_CR28","doi-asserted-by":"crossref","unstructured":"Rini BI, et al. Time to resolution of axitinib-related adverse events after treatment interruption in patients with advanced renal cell carcinoma.\u00a0Clin Genitourin Cancer. 2021;19(5):e306\u201312.","DOI":"10.1016\/j.clgc.2021.03.019"},{"issue":"23","key":"1196_CR29","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1056\/NEJMoa003013","volume":"345","author":"RC Flanigan","year":"2001","unstructured":"Flanigan RC, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001;345(23):1655\u20139.","journal-title":"N Engl J Med"},{"issue":"9286","key":"1196_CR30","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1016\/S0140-6736(01)06103-7","volume":"358","author":"GH Mickisch","year":"2001","unstructured":"Mickisch GH, et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet. 2001;358(9286):966\u201370.","journal-title":"Lancet"},{"key":"1196_CR31","doi-asserted-by":"crossref","unstructured":"M\u00e9jean A, et al. Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. N Engl J Med. 2018;379(5):417\u2013427. CARMENA trial which demonstrated noninferior of sunitinib alone vs nephrectomy followed by sunitinib in MSKCC intermediate\/poor risk.","DOI":"10.1056\/NEJMc1811532"},{"key":"1196_CR32","unstructured":"M\u00e9jean A, et al. Sunitinib alone or after nephrectomy for patients with metastatic renal cell carcinoma: is there still a role for cytoreductive nephrectomy? Eur Urol. 2021;\u00a080(4):417\u2013424.\u00a0Extended follow-up of CARMENA. The results of CARMENA trial suggest upfront cytoreductive nephrectomy should only be offered in selected patients (low disease burden and IMDC 0 or 1 risk)."},{"issue":"2","key":"1196_CR33","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1470-2045(12)70559-4","volume":"14","author":"DY Heng","year":"2013","unstructured":"Heng DY, et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol. 2013;14(2):141\u20138.","journal-title":"Lancet Oncol"},{"issue":"2","key":"1196_CR34","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1001\/jamaoncol.2018.5543","volume":"5","author":"A Bex","year":"2019","unstructured":"Bex A, et al. Comparison of immediate vs deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: the SURTIME randomized clinical trial. JAMA Oncol. 2019;5(2):164\u201370.","journal-title":"JAMA Oncol"},{"key":"1196_CR35","unstructured":"Rini BI, et al. Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial. Lancet Oncol. 2016;17(9):1317\u201324. This study demonstrated a subset of mRCC patients can be safely followed by active surveillance to prevent toxicities from systmeic therapy."},{"issue":"13","key":"1196_CR36","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1002\/cncr.33494","volume":"127","author":"MR Harrison","year":"2021","unstructured":"Harrison MR, et al. Active surveillance of metastatic renal cell carcinoma: results from a prospective observational study (MaRCC). Cancer. 2021;127(13):2204\u201312.","journal-title":"Cancer"},{"key":"1196_CR37","doi-asserted-by":"crossref","unstructured":"Tucker MD, Rini BI. Predicting Response to Immunotherapy in Metastatic Renal Cell Carcinoma. Cancers (Basel). 2020;12(9):2662.","DOI":"10.3390\/cancers12092662"},{"issue":"6","key":"1196_CR38","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/s41591-018-0053-3","volume":"24","author":"DF McDermott","year":"2018","unstructured":"McDermott DF, et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med. 2018;24(6):749\u201357.","journal-title":"Nat Med"},{"issue":"11","key":"1196_CR39","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1038\/s41591-020-1044-8","volume":"26","author":"RJ Motzer","year":"2020","unstructured":"Motzer RJ, et al. Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial. Nat Med. 2020;26(11):1733\u201341.","journal-title":"Nat Med"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-022-01196-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-022-01196-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-022-01196-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,28]],"date-time":"2023-01-28T12:35:27Z","timestamp":1674909327000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-022-01196-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,5]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["1196"],"URL":"https:\/\/doi.org\/10.1007\/s11912-022-01196-1","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,5]]},"assertion":[{"value":"30 September 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Yu-Wei Chen declares that he has no conflict of interest. Brian I. Rini has received research funding (paid to his institution) from Pfizer, Hoffman-LaRoche, Incyte Corporation, AstraZeneca, TARIS Biomedical, Seattle Genetics, Arrowhead Pharmaceuticals, Immunomedics, Bristol-Myers Squibb, Mirati Therapeutics, Merck, Surface Oncology, Dragonfly Therapeutics, Aravive, and Exelixis; has received compensation for service as a consultant from Bristol-Myers Squibb, Pfizer, Genentech\/Roche, Aveo Oncology, Synthorx, Compugen, Merck, Corvus Pharmaceuticals, Surface Oncology, 3D Medicines, Aravive, Alkermes, Arrowhead Pharmaceuticals, GlaxoSmithKline, Shionogi, Eisai, and NiKang Therapeutics; and owns stock in PTC Therapeutics.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}